Risk Stratification

Combination Testing With ThyGeNEXT® and ThyraMIR® Provides Accurate Reclassification1

ThyGeNEXT® + ThyraMIR® Combination Testing Performance1

High NPV

  • Significant decrease in unnecessary surgeries
  • 85% reduction relative to cytology alone (P<0.01)

Testing helps to risk-stratify the need for or extent of surgery needed

ATA and NCCN Guidelines support testing for nodules with a B-III or B-IV cytology diagnosis

Markers

Strategically Designed Panel for the Optimal Management of Thyroid Nodules

Newly added TERT and ALK mutations can reliably help to predict aggressive biological features of thyroid cancer, including:

  • Large tumor size
  • Higher patient mortality
  • Likelihood of lymph node metastasis
  • Higher rate of recurrence post-treatment
  • Higher clinical stage at time of cancer detection
  • Likelihood of cancer spreading beyond the thyroid
  • Increased risk for tumor vascular invasion
  • Potential for treatment failure